[go: up one dir, main page]

WO2001030989A3 - Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique - Google Patents

Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique Download PDF

Info

Publication number
WO2001030989A3
WO2001030989A3 PCT/IB2000/001557 IB0001557W WO0130989A3 WO 2001030989 A3 WO2001030989 A3 WO 2001030989A3 IB 0001557 W IB0001557 W IB 0001557W WO 0130989 A3 WO0130989 A3 WO 0130989A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecules
proteins
populations
creating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/001557
Other languages
English (en)
Other versions
WO2001030989A2 (fr
Inventor
Wolfgang A Renner
Lars Nieba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Priority to EP00969738A priority Critical patent/EP1226238A2/fr
Priority to AU79389/00A priority patent/AU7938900A/en
Publication of WO2001030989A2 publication Critical patent/WO2001030989A2/fr
Publication of WO2001030989A3 publication Critical patent/WO2001030989A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne les domaines de biologie moléculaire, de virologie, d'immunologie et de médecine. Elle concerne des procédés de création de populations divergentes de molécules et de protéines d'acide nucléique, ainsi que des molécules et protéines produites selon ces procédés. Elle concerne enfin des techniques de production de populations d'antigènes et de déterminants antigéniques utilisés pour produire des vaccins destinés au traitement de maladies infectieuses ainsi que des produits pharmaceutiques visant la prévention de cancers.
PCT/IB2000/001557 1999-10-27 2000-10-26 Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique Ceased WO2001030989A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00969738A EP1226238A2 (fr) 1999-10-27 2000-10-26 Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique
AU79389/00A AU7938900A (en) 1999-10-27 2000-10-26 Method for creating divergent populations of nucleic acid molecules and proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16179699P 1999-10-27 1999-10-27
US60/161,796 1999-10-27

Publications (2)

Publication Number Publication Date
WO2001030989A2 WO2001030989A2 (fr) 2001-05-03
WO2001030989A3 true WO2001030989A3 (fr) 2001-11-22

Family

ID=22582767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001557 Ceased WO2001030989A2 (fr) 1999-10-27 2000-10-26 Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique

Country Status (3)

Country Link
EP (1) EP1226238A2 (fr)
AU (1) AU7938900A (fr)
WO (1) WO2001030989A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110482A1 (fr) * 2003-06-13 2004-12-23 Isis Innovation Limited Vaccins ameliores
US7303898B2 (en) 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
WO2009043096A1 (fr) * 2007-10-05 2009-04-09 Arana Therapeutics (Vic) Pty Ltd Procédé amélioré de mutagenèse
NZ589495A (en) 2008-05-23 2012-06-29 Fit Biotech Oy Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018324A1 (fr) * 1996-10-28 1998-05-07 The University Of Washington Induction d'une mutation virale par incorporation d'analogues de ribonucleosides a defaut de codage dans un arn viral
WO1998051809A1 (fr) * 1997-05-12 1998-11-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Vecteurs multigenes derives de hsv
WO1999050432A1 (fr) * 1998-03-27 1999-10-07 Cytos Biotechnology Ag Systeme d'expression des genes d'alphavirus a induction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018324A1 (fr) * 1996-10-28 1998-05-07 The University Of Washington Induction d'une mutation virale par incorporation d'analogues de ribonucleosides a defaut de codage dans un arn viral
WO1998051809A1 (fr) * 1997-05-12 1998-11-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Vecteurs multigenes derives de hsv
WO1999050432A1 (fr) * 1998-03-27 1999-10-07 Cytos Biotechnology Ag Systeme d'expression des genes d'alphavirus a induction

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARTHOLOMEUSZ A ET AL: "SIGNIFICANCE OF MUTATIONS IN THE HEPATITIS B VIRUS POLYMERASE SELECTED BY NUCLEOSIDE ANALOGUES AND IMPLICATIONS FOR CONTROLLING CHRONIC DISEASE", VIRAL HEPATITIS REVIEWS,US,SAUNDERS, PHILADELPHIA, PA, vol. 4, no. 3, 1998, pages 167 - 187, XP000863517, ISSN: 1081-7050 *
FROLOV I ET AL: "ALPHAVIRUS-BASED EXPRESSION VECTORS: STRATEGIES AND APPLICATIONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 93, no. 21, 1996, pages 11371 - 11377, XP000910193, ISSN: 0027-8424 *
HAHN Y S ET AL: "MAPPING OF RNA-NEGATIVE TEMPERATURE-SENSITIVE MUTANTS OF SINDBIS VIRUS COMPLEMENTATION GROUP F MUTANTS HAVE LESIONS IN NSP4", JOURNAL OF VIROLOGY, vol. 63, no. 3, 1989, pages 1194 - 1202, XP000984665, ISSN: 0022-538X *
SCHLESINGER SONDRA ET AL: "Alphavirus vectors for gene expression and vaccines.", CURRENT OPINION IN BIOTECHNOLOGY, vol. 10, no. 5, October 1999 (1999-10-01), pages 434 - 438, XP000986381, ISSN: 0958-1669 *
TAKAHASHI M. ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 8, January 1988 (1988-01-01), pages 347 - 352, XP000984655 *
TUBULEKAS I ET AL: "Alphavirus expression vectors and their use as recombinant vaccines: a minireview", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 190, no. 1, 29 April 1997 (1997-04-29), pages 191 - 195, XP004064401, ISSN: 0378-1119 *
WRIGHT M C AND JOYCE G F: "Continuous in vitro evolution of catalytic function", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, no. 276, 1997, pages 614 - 617, XP002074723, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
AU7938900A (en) 2001-05-08
EP1226238A2 (fr) 2002-07-31
WO2001030989A2 (fr) 2001-05-03

Similar Documents

Publication Publication Date Title
WO2002056905A3 (fr) Jeu ordonne d'echantillons d'antigenes moleculaires
WO2002034205A3 (fr) Utilisation des proteines du stress pour stimuler la reponse immunitaire
ATE447967T1 (de) Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
WO2000075336A3 (fr) Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
WO2004007538A3 (fr) Reseaux d'antigenes moleculaires
WO2004084939A3 (fr) Conjugues porteurs de peptides du vih
IL166227A0 (en) Vaccine compositions containing amyloid beta1-6 antigen arrays
CN103370413B (zh) Dna表达构建体
WO2003039225A3 (fr) Ensemble ordonne d'antigenes destines au traitement de maladies osseuses
WO2009080823A3 (fr) Conjugués du ngf et leurs utilisations
WO2005117983A3 (fr) Conjugues entraineurs des peptides du tnf
WO2005068639A3 (fr) Conjugues a base de ghreline et d'un vehicule
DK1015494T3 (da) Fremgangsmåde til fremstilling af katalytiske antistoffer
WO2001030989A3 (fr) Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique
WO2006027300A3 (fr) Conjugues vecteurs des peptides de gonadoliberine (gnrh)
WO2001035989A3 (fr) Nouvelle utilisation d'anticorps en tant que vaccins
DE502004005784D1 (de) Mittel zur behandlung von infektionen mit leishmanien
NO20020615L (no) Vaksine
WO2003059386A3 (fr) Conjuges-vecteurs de proteines prion
BRPI0513741A (pt) processo de melhoria da imunogeneicidade de um imunogene, antìgeno ou hapteno, complexo imunogênico, ácido nucleico e utilização de um complexo imunogênico
WO2002038611A3 (fr) Procede de production d'anticorps par immunisation avec des conjugues de molecules couplees a des proteines a charge modifiee
MXPA04003900A (es) Disposiciones de antigenos para el tratamiento de enfermedades oseas.
AU2002223860A1 (en) Nucleic acid vaccine comprising a fusion protein including an adjuvant sequence from a plant viral coat protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000969738

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000969738

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000969738

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP